October 24th 2019
Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.
October 21st 2019
Using dual checkpoint inhibitors in patients with hepatocellular carcinoma is demonstrating activity with a manageable safety profile in both second-line and perioperative settings.
October 12th 2016
While tomosynthesis has been described by the oncology community as one of the biggest improvements in breast cancer screening, the technology that renders 3D-like images of the breast does carry limitations.
October 11th 2016
PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.